{"id":"mesothelin","name":"Mesothelin","symbol":"MSLN","route":"/targets/mesothelin/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:7371","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000102854","uniprot":"https://www.uniprot.org/uniprotkb/Q13421/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/Q13421","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL3712878","open-targets":"https://platform.opentargets.org/target/ENSG00000102854","civic":"https://civicdb.org/genes/10232/summary","oncokb":"https://www.oncokb.org/gene/MSLN","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=MSLN","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=MSLN","depmap":"https://depmap.org/portal/gene/MSLN?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000102854-MSLN","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/10232","omim":"https://www.omim.org/entry/601051"}],"products":[{"id":"anetumab-ravtansine","name":"Anetumab ravtansine","status":"negative","modality":"Antibody-drug conjugate (anti-mesothelin antibody, DM4 payload), intravenous","route":"/drugs/anetumab-ravtansine/"},{"id":"eb-mf-car-nk-01","name":"EB-MF-CAR-NK-01","status":"phase-2","modality":"bispecific antibody","route":"/drugs/eb-mf-car-nk-01/"}],"trials":[{"id":"anetumab-vs-vinorelbine-mpm","name":"Anetumab ravtansine versus vinorelbine in relapsed mesothelin-positive pleural mesothelioma","nct":"NCT02610140","phase":"2","status":"negative"},{"id":"eclipse","name":"ECLIPSE (GVAX pancreas and CRS-207)","nct":"NCT02004262","phase":"2","status":"negative"},{"id":"nci-anetumab-pembrolizumab-mpm","name":"Pembrolizumab with or without anetumab ravtansine in mesothelin-positive pleural mesothelioma (NCI)","nct":"NCT03126630","phase":"1/2","status":"active"},{"id":"nct07083323","name":"A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors","nct":"NCT07083323","phase":"1/2","status":"recruiting"},{"id":"nct07467863","name":"Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC","nct":"NCT07467863","phase":"1/2","status":"recruiting"},{"id":"nct07641023","name":"Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC","nct":"NCT07641023","phase":"1/2","status":"recruiting"},{"id":"nct07510815","name":"Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma","nct":"NCT07510815","phase":"1/2","status":"recruiting"},{"id":"nct07480954","name":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","nct":"NCT07480954","phase":"1/2","status":"recruiting"},{"id":"nct07066995","name":"Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer","nct":"NCT07066995","phase":"1/2","status":"recruiting"}],"pathways":[],"companies":["bayer"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}